Kymera Therapeutics Inc (KYMR) - Total Liabilities
Based on the latest financial reports, Kymera Therapeutics Inc (KYMR) has total liabilities worth $129.38 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Kymera Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Kymera Therapeutics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Kymera Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Kymera Therapeutics Inc (KYMR) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Kymera Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Kymera Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CITIC Metal Co. Ltd. A
SHG:601061
|
China | CN¥33.01 Billion |
|
KAWASAKI KISEN K. ADR/1/2
F:KLI
|
Germany | €505.03 Billion |
|
IAMGold Corporation
TO:IMG
|
Canada | CA$1.79 Billion |
|
Norwegian Cruise Line Holdings Ltd
NYSE:NCLH
|
USA | $21.36 Billion |
|
Frontline Ltd
NYSE:FRO
|
USA | $3.24 Billion |
|
Hengyi Petrochemical Co Ltd
SHE:000703
|
China | CN¥82.21 Billion |
|
DISCOVERY LTD(UNSP.ADR)/3
F:D3H0
|
Germany | €288.99 Billion |
|
Orion Oyj B
HE:ORNBV
|
Finland | €726.20 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Kymera Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Kymera Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kymera Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kymera Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Kymera Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $163.15 Million | +14.56% |
| 2024-12-31 | $142.42 Million | -21.22% |
| 2023-12-31 | $180.79 Million | +60.01% |
| 2022-12-31 | $112.98 Million | -22.76% |
| 2021-12-31 | $146.27 Million | -28.05% |
| 2020-12-31 | $203.29 Million | +6.37% |
| 2019-12-31 | $191.11 Million | +142.93% |
| 2018-12-31 | $78.67 Million | -- |
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CR… Read more